Healthy Skepticism Library item: 18756
Warning: This library includes all items relevant to health product marketing that we are aware of regardless of quality. Often we do not agree with all or part of the contents.
Publication type: news
Study finds doctors not immune to pharmaceutical promotion
YFile 2010 Oct 21
Pharmaceutical promotion may cause doctors to prescribe more expensively, less appropriately and more often, according to a new study co-authored by physician and York Professor Joel Lexchin.
The findings, published Wednesday in the journal, PLoS Medicine, offer a broad look at the relationship between doctors’ prescribing habits and their exposure to information provided by drug companies. Researchers analyzed 58 separate studies of this phenomenon from Canada, the United States, Europe and Australia, dating from the 1960s.
“Many doctors claim they aren’t influenced by the information provided by pharmaceutical companies. Our research clearly shows that they are – and the influence is negative,” says Lexchin, a professor in the School of Health Policy & Management in York’s Faculty of Health and an emergency physician in Toronto.
“Unfortunately, patients are the ones getting a raw deal. If doctors are inundated with advertising from brand- name companies, they are more likely to prescribe that brand name, regardless of whether it’s best for the patient.”
All but one of the studies suggested that exposure to promotional information was associated with lower prescribing quality; the one remaining study detected no association. Findings also show that promotional information led to more frequent prescribing; studies dealing with this correlation either showed a spike in prescribing or detected no association. Researchers also established a link between promotion and higher prescribing costs.
Lexchin says Canadian drug companies spend big money on marketing their products to physicians, to the detriment of other priorities such as research and development.
“In Canada, companies are estimated to be spending anywhere between $2.4 and $4.75 billion annually on promotion, one of the major reasons why spending on brand-name drugs was rising at a rate of just under 10 per cent annually until two years ago,” he says.
A limitation of the research is that most studies were observational in nature, meaning that the majority of physicians who participated were not randomly selected.
The researchers found no evidence that drug companies’ promotional efforts improve prescribing behaviour in any way, but, says Lexchin, “that doesn’t entirely exclude the possibility that prescribing might sometimes be improved.” However, he adds, “As a precaution, we recommend that physicians avoid exposure to the information provided by pharmaceutical companies.”
The study, “Information from pharmaceutical companies and the quality, quantity and cost of physicians’ prescribing: a systematic review”, was led by Geoffrey Spurling, a professor at the University of Queensland, Brisbane, Australia. To read it, visit the PLoS Medicine website.